<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
January 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>GENEREX BIOTECHNOLOGY CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">000-29169</TD>
    <TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">98-0178636</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(State or other</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Commission File</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(I.R.S Employer Identification</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">jurisdiction of</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Number)</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Incorporation)</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-weight: bold; text-align: center">33 Harbour Square, Suite 202, Toronto, Ontario</TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center">M5J 2G2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Canada</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (416) 364-2551</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former name or former address, if changed
since last report.)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 97%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Wingdings">&uml;</TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Item 1.01.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entry
into a Material Definitive Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unregistered
Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 31, 2012, Generex Biotechnology Corporation
(the &ldquo;Company&rdquo;) entered into a securities purchase agreement with certain investors, pursuant to which the Company
agreed to sell an aggregate of 2,000 shares of its newly designated non-voting Series B 9% Convertible Preferred Stock (&ldquo;convertible
preferred stock&rdquo;) and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion
of the convertible preferred stock (&ldquo;warrants&rdquo;). The convertible preferred stock and warrants will be sold in units,
with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company&rsquo;s
common stock issuable upon conversion of such share of convertible preferred stock. Each unit will be sold at a negotiated price
of $1,000, for an aggregate purchase price of $2,000,000. An aggregate of 26,666,666 shares of the Company&rsquo;s common stock
are issuable upon conversion of, or exercise of, the convertible preferred stock and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Subject to certain ownership limitations, the
convertible preferred stock will be convertible at the option of the holder at any time into shares of the Company&rsquo;s common
stock at an effective conversion price of $0.15 per share, and will accrue a 9% dividend until February 1, 2015 and, beginning
on February 1, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend
will be payable quarterly on September 30, December 31, March 31 and June 30, beginning on the first such date after the original
issue date and on each conversion date in cash, or at the Company&rsquo;s option, in shares of common stock. In the event that
the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred
stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly
dividends paid on such converted preferred stock before the relevant conversion date. Such &ldquo;make-whole payment&rdquo; may
be made in cash or, at the Company&rsquo;s option, in shares of its common stock. In addition, beginning February 1, 2015, the
Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same
form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if
such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The conversion price of the convertible preferred
stock will be subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization
transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company
sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price
per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders
of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or
issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their
shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially
all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive,
upon conversion of their shares, any securities or other consideration received by the holders of the Company&rsquo;s common stock
pursuant to the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company may become obligated to redeem the
convertible preferred stock in cash upon the occurrence of certain triggering events, including, material breach of certain contractual
obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence
of certain insolvency events relating to the Company, or the failure of the Company&rsquo;s common stock to continue to be listed
or quoted for trading on one or more specified United States securities exchanges or regulated quotation service. Upon the occurrence
of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder&rsquo;s shares
of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of
18% on all of such holder&rsquo;s outstanding convertible preferred stock. Late fees will apply on all redemption amounts not paid
within five trading days of the payment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the event that the Company fails to timely
deliver certificates for shares of common stock issuable upon conversion of convertible preferred stock (&ldquo;conversion shares&rdquo;)
and the holder is required by its brokerage firm to purchase (in an open market transaction or otherwise) or such holder&rsquo;s
brokerage firm otherwise purchases, shares of common stock to deliver in satisfaction of a sale by such holder of the conversion
shares, the Company will:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 74.2pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pay
the holder in cash the amount, if any, by which such holder&rsquo;s total purchase price (including any brokerage commissions)
for the shares of common stock purchased exceeds the product of (1) the aggregate number of conversion shares due to the holder
multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including
any brokerage commissions) and</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 74.2pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 74.2pt; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at
the option of such holder, either reissue (if surrendered) the shares of convertible preferred stock equal to the number of shares
of convertible preferred stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to
such holder the number of shares of common stock that would have been issued if the Company had timely complied with its delivery
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Subject to certain ownership limitations, the
warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at
an exercise price of $0.15 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares
issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar
recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares
of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities
convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price,
except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or
rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same
extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation,
sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive,
upon exercise of their warrants, any securities or other consideration received by the holders of the Company&rsquo;s common stock
pursuant to the fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The securities purchase agreement and the certificate
of designation authorizing the convertible preferred stock include certain agreements and covenants for the benefit of the holders
of the convertible preferred stock, including restrictions on the Company&rsquo;s ability to amend its certificate of incorporation
and bylaws, pay cash dividends or distributions with respect to its common stock or other junior securities, repurchase more than
a <U>de</U> <U>minimis</U> number of shares of its common stock or other junior, securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The securities purchase agreement also prohibits
the Company from issuing additional equity securities until 60 days after the effective date of a registration statement covering
the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock and issuing additional
debt or equity securities with variable a conversion or exercise price for a period of 12 months after the closing of the transaction.
Under the securities purchase agreement, the Company may not undertake a reverse or forward stock split or reclassification of
its common stock except for a reverse stock split made in conjunction with a listing of the common stock on a national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">With very limited exceptions, the investors
will have a pro rata right of first refusal in respect of participation in any private debt or equity financings undertaken by
the Company during the 12 months following the closing of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The investors may, immediately upon written
notice to the Company, terminate the securities purchase agreement at any time, if the closing has not been consummated on the
closing date; provided, however, no such termination will affect the right of any party to sue for any breach by any other party.
The securities purchase agreement contains representations and warranties and covenants for each party, which must be true and
have been performed at each closing. The Company has agreed to indemnify and hold the investors harmless against certain liabilities
in connection with the issuance and sale of the convertible preferred stock and warrants under the securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The net cash proceeds to the Company from the
offering at the closing, after deducting the finders&rsquo; fees and the Company&rsquo;s estimated offering expenses, and excluding
the proceeds, if any, from the exercise of the warrants issued in the offering, are expected to be approximately $1,975,000. In
consideration for introducing the Company to the investors, the Company will pay Seahawk Capital Partners, Inc., a finders&rsquo;
fee equal to 8% of the ross proceeds from the closing ($160,000). The finders&rsquo; fee will be paid in shares of common stock
based on a per share price of $0.15 (1,066,667 shares). The transaction is expected to close on or about February 1, 2012, subject
to satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company and the investors entered into the
new securities purchase agreement pursuant to the investors&rsquo; additional investment rights existing under a July 8, 2011 securities
purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The shares of convertible preferred stock, warrants,
the shares of common stock underlying the convertible preferred stock and the warrants, the shares of common stock issuable in
lieu of the cash payment of dividends on the convertible preferred stock and the shares of common stock payable and issuable as
finders&rsquo; fees were offered privately pursuant to Rule 506 of Regulation D under the Securities Act of 1933. The Company and
the investors have entered into a registration rights agreement pursuant to which the Company has agreed to file a registration
statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of
the preferred stock, issuable as dividends on the preferred stock, issuable upon exercise of the warrants and issued as a finders&rsquo;
fee to Seahawk Capital Partners. The Company has agreed to file the registration statement within 45 days after closing and to
use its best efforts to have the registration statement declared effective within 120 days after closing. If these deadlines are
not met, the Company will liable for liquidated damages up to 6% of the purchase price under the securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the securities purchase agreement
provides that if, during the period beginning six months after the issuance of the warrants and continuing until such time that
all of the securities may be sold without the Company meeting the current public information requirement under Securities Act rule
144(c)(1), the Company fails to meet such requirement, the Company will pay liquidate damages equal to 2.0% of the purchase price
paid by each investor. Such payments will be made in cash every 30 days until current public information for the Company is available
or is no longer required for the investors to rely on Rule 144 to transfer the securities (including underlying securities) acquired
under the securities purchase agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Contemporaneous with entering into the securities
purchase agreement, the Company and the investors also agreed to certain clarifications to the exercise price adjustment provisions
under the outstanding warrants issued in July 2011. Under that agreement, the parties agreed to an exercise price of $0.15 per
share for the warrants to purchase 14,500,000 shares of common stock (24,166,664 shares after the anti-dilution adjustment required
under the terms of the warrants), which were in the process of being exercised prior to the parties entering into the securities
purchase agreement, and unexercised outstanding warrants to purchase 2,666,666 shares of common stock (4,444,442 shares following
the required anti-dilution adjustment). .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The foregoing description of the terms of the
certificate of designation of preferences, rights and limitations of the convertible preferred stock, the securities purchase agreement,
the form of warrant, and the registration rights agreement are subject to, and qualified in their entirety by, such documents attached
hereto as Exhibits 3.1, 4.1, 4.2, and 4.3, respectively, and incorporated herein by reference. A copy of the press release announcing
the private placement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Item 5.03</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 1, 2012, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of the Series B 9% Convertible Preferred Stock with the Secretary of State
of the State of Delaware. The description of the certificate of designation and the convertible preferred stock contained in Items
1.01 and 3.02 above are incorporated herein by reference and are subject to, and qualified in their entirety by, the certificate
of designation attached hereto as Exhibit 3.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial
Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The list of exhibits called for by this Item
is incorporated by reference to the Exhibit Index filed with this report.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 53%; font-weight: bold">GENEREX BIOTECHNOLOGY CORPORATION.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: February 1, 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;/s/ Mark A. Fletcher</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Mark A. Fletcher</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Exhibit Index </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold; border-bottom: Black 1pt solid">Exhibit No.</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 86%; font-weight: bold; border-bottom: Black 1pt solid">Description</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certificate of Designation of Preferences, Rights and Limitations of Series B 9% Convertible Preferred Stock</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Securities Purchase Agreement, dated January 31, 2012, by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Common Stock Warrant</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.3</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Registration Rights Agreement by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated January 31, 2012</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: right; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300981_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 34721}]
{"company-data": {"conformed-name": "GENEREX BIOTECHNOLOGY CORP", "cik": "0001059784", "assigned-sic": "2834", "irs-number": "820490211", "state-of-incorporation": "DE", "fiscal-year-end": "0731"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-25169", "film-number": "12561217"}, "business-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CANADA", "state": "A1", "zip": "M5J 2G2", "phone": "4163642551"}, "mail-address": {"street1": "33 HARBOUR SQ", "street2": "STE 202", "city": "TORONTO ONTARIO CA", "state": "A1", "zip": "M5J 2G2"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 31, 2012
GENEREX BIOTECHNOLOGY CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
000-29169
98-0178636
(State or other
(Commission File
(I.R.S Employer Identification
jurisdiction of
Number)
No.)
Incorporation)
33 Harbour Square, Suite 202, Toronto, Ontario
M5J 2G2
Canada
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code: (416) 364-2551
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01.         Entry
into a Material Definitive Agreement
Item 3.02          Unregistered
Sales of Equity Securities.
On January 31, 2012, Generex Biotechnology Corporation
(the "Company") entered into a securities purchase agreement with certain investors, pursuant to which the Company
agreed to sell an aggregate of 2,000 shares of its newly designated non-voting Series B 9% Convertible Preferred Stock ("convertible
preferred stock") and warrants to purchase up to an aggregate of 100% of the shares of its common stock issuable upon conversion
of the convertible preferred stock ("warrants"). The convertible preferred stock and warrants will be sold in units,
with each unit consisting of one share of convertible preferred stock and a warrant to purchase 100% of the shares of the Company's
common stock issuable upon conversion of such share of convertible preferred stock. Each unit will be sold at a negotiated price
of $1,000, for an aggregate purchase price of $2,000,000. An aggregate of 26,666,666 shares of the Company's common stock
are issuable upon conversion of, or exercise of, the convertible preferred stock and warrants.
Subject to certain ownership limitations, the
convertible preferred stock will be convertible at the option of the holder at any time into shares of the Company's common
stock at an effective conversion price of $0.15 per share, and will accrue a 9% dividend until February 1, 2015 and, beginning
on February 1, 2015 and on each one year anniversary thereafter, such dividend rate will increase by an additional 3%. The dividend
will be payable quarterly on September 30, December 31, March 31 and June 30, beginning on the first such date after the original
issue date and on each conversion date in cash, or at the Company's option, in shares of common stock. In the event that
the convertible preferred stock is converted prior to February 1, 2015, the Company will pay the holder of the converted preferred
stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly
dividends paid on such converted preferred stock before the relevant conversion date. Such "make-whole payment" may
be made in cash or, at the Company's option, in shares of its common stock. In addition, beginning February 1, 2015, the
Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same
form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if
such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends.
The conversion price of the convertible preferred
stock will be subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization
transactions and certain pro-rata distributions to common stockholders. The conversion price will also be adjusted if the Company
sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price
per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders
of convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or
issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their
shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially
all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock will be entitled to receive,
upon conversion of their shares, any securities or other consideration received by the holders of the Company's common stock
pursuant to the fundamental transaction.
The Company may become obligated to redeem the
convertible preferred stock in cash upon the occurrence of certain triggering events, including, material breach of certain contractual
obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence
of certain insolvency events relating to the Company, or the failure of the Company's common stock to continue to be listed
or quoted for trading on one or more specified United States securities exchanges or regulated quotation service. Upon the occurrence
of certain triggering events, each holder of convertible preferred stock will have the option to redeem such holder's shares
of convertible preferred stock for a redemption price payable in shares of common stock or receive an increased dividend rate of
18% on all of such holder's outstanding convertible preferred stock. Late fees will apply on all redemption amounts not paid
within five trading days of the payment date.
In the event that the Company fails to timely
deliver certificates for shares of common stock issuable upon conversion of convertible preferred stock ("conversion shares")
and the holder is required by its brokerage firm to purchase (in an open market transaction or otherwise) or such holder's
brokerage firm otherwise purchases, shares of common stock to deliver in satisfaction of a sale by such holder of the conversion
shares, the Company will:
·
pay
the holder in cash the amount, if any, by which such holder's total purchase price (including any brokerage commissions)
for the shares of common stock purchased exceeds the product of (1) the aggregate number of conversion shares due to the holder
multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including
any brokerage commissions) and
·
at
the option of such holder, either reissue (if surrendered) the shares of convertible preferred stock equal to the number of shares
of convertible preferred stock submitted for conversion (in which case, such conversion shall be deemed rescinded) or deliver to
such holder the number of shares of common stock that would have been issued if the Company had timely complied with its delivery
requirements.
Subject to certain ownership limitations, the
warrants will be exercisable at any time after their date of issuance and on or before the fifth-year anniversary thereafter at
an exercise price of $0.15 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares
issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar
recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares
of common stock issuable upon exercise will also be adjusted if the Company sells or grants any shares of common stock or securities
convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price,
except in the event of certain exempt issuances. In addition, the warrant holders will be entitled to receive any securities or
rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same
extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation,
sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive,
upon exercise of their warrants, any securities or other consideration received by the holders of the Company's common stock
pursuant to the fundamental transaction.
The securities purchase agreement and the certificate
of designation authorizing the convertible preferred stock include certain agreements and covenants for the benefit of the holders
of the convertible preferred stock, including restrictions on the Company's ability to amend its certificate of incorporation
and bylaws, pay cash dividends or distributions with respect to its common stock or other junior securities, repurchase more than
a
de
minimis
number of shares of its common stock or other junior, securities.
The securities purchase agreement also prohibits
the Company from issuing additional equity securities until 60 days after the effective date of a registration statement covering
the resale of the common stock issuable upon exercise of the warrants and conversion of the preferred stock and issuing additional
debt or equity securities with variable a conversion or exercise price for a period of 12 months after the closing of the transaction.
Under the securities purchase agreement, the Company may not undertake a reverse or forward stock split or reclassification of
its common stock except for a reverse stock split made in conjunction with a listing of the common stock on a national securities
exchange.
With very limited exceptions, the investors
will have a pro rata right of first refusal in respect of participation in any private debt or equity financings undertaken by
the Company during the 12 months following the closing of the transaction.
The investors may, immediately upon written
notice to the Company, terminate the securities purchase agreement at any time, if the closing has not been consummated on the
closing date; provided, however, no such termination will affect the right of any party to sue for any breach by any other party.
The securities purchase agreement contains representations and warranties and covenants for each party, which must be true and
have been performed at each closing. The Company has agreed to indemnify and hold the investors harmless against certain liabilities
in connection with the issuance and sale of the convertible preferred stock and warrants under the securities purchase agreement.
The net cash proceeds to the Company from the
offering at the closing, after deducting the finders' fees and the Company's estimated offering expenses, and excluding
the proceeds, if any, from the exercise of the warrants issued in the offering, are expected to be approximately $1,975,000. In
consideration for introducing the Company to the investors, the Company will pay Seahawk Capital Partners, Inc., a finders'
fee equal to 8% of the ross proceeds from the closing ($160,000). The finders' fee will be paid in shares of common stock
based on a per share price of $0.15 (1,066,667 shares). The transaction is expected to close on or about February 1, 2012, subject
to satisfaction of customary closing conditions.
The Company and the investors entered into the
new securities purchase agreement pursuant to the investors' additional investment rights existing under a July 8, 2011 securities
purchase agreement.
The shares of convertible preferred stock, warrants,
the shares of common stock underlying the convertible preferred stock and the warrants, the shares of common stock issuable in
lieu of the cash payment of dividends on the convertible preferred stock and the shares of common stock payable and issuable as
finders' fees were offered privately pursuant to Rule 506 of Regulation D under the Securities Act of 1933. The Company and
the investors have entered into a registration rights agreement pursuant to which the Company has agreed to file a registration
statement with the Securities and Exchange Commission covering the public resale of the common stock issuable upon conversion of
the preferred stock, issuable as dividends on the preferred stock, issuable upon exercise of the warrants and issued as a finders'
fee to Seahawk Capital Partners. The Company has agreed to file the registration statement within 45 days after closing and to
use its best efforts to have the registration statement declared effective within 120 days after closing. If these deadlines are
not met, the Company will liable for liquidated damages up to 6% of the purchase price under the securities purchase agreement.
In addition, the securities purchase agreement
provides that if, during the period beginning six months after the issuance of the warrants and continuing until such time that
all of the securities may be sold without the Company meeting the current public information requirement under Securities Act rule
144(c)(1), the Company fails to meet such requirement, the Company will pay liquidate damages equal to 2.0% of the purchase price
paid by each investor. Such payments will be made in cash every 30 days until current public information for the Company is available
or is no longer required for the investors to rely on Rule 144 to transfer the securities (including underlying securities) acquired
under the securities purchase agreement.
Contemporaneous with entering into the securities
purchase agreement, the Company and the investors also agreed to certain clarifications to the exercise price adjustment provisions
under the outstanding warrants issued in July 2011. Under that agreement, the parties agreed to an exercise price of $0.15 per
share for the warrants to purchase 14,500,000 shares of common stock (24,166,664 shares after the anti-dilution adjustment required
under the terms of the warrants), which were in the process of being exercised prior to the parties entering into the securities
purchase agreement, and unexercised outstanding warrants to purchase 2,666,666 shares of common stock (4,444,442 shares following
the required anti-dilution adjustment). .
The foregoing description of the terms of the
certificate of designation of preferences, rights and limitations of the convertible preferred stock, the securities purchase agreement,
the form of warrant, and the registration rights agreement are subject to, and qualified in their entirety by, such documents attached
hereto as Exhibits 3.1, 4.1, 4.2, and 4.3, respectively, and incorporated herein by reference. A copy of the press release announcing
the private placement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 5.03
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On February 1, 2012, the Company filed a Certificate
of Designation of Preferences, Rights and Limitations of the Series B 9% Convertible Preferred Stock with the Secretary of State
of the State of Delaware. The description of the certificate of designation and the convertible preferred stock contained in Items
1.01 and 3.02 above are incorporated herein by reference and are subject to, and qualified in their entirety by, the certificate
of designation attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01
Financial
Statements and Exhibits.
(d) Exhibits.
The list of exhibits called for by this Item
is incorporated by reference to the Exhibit Index filed with this report.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION.
Date: February 1, 2012
/s/ Mark A. Fletcher
Mark A. Fletcher
President and Chief Executive Officer
Exhibit Index
Exhibit No.
Description
3.1
Certificate of Designation of Preferences, Rights and Limitations of Series B 9% Convertible Preferred Stock
4.1
Form of Securities Purchase Agreement, dated January 31, 2012, by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto
4.2
Form of Common Stock Warrant
4.3
Form of Registration Rights Agreement by and among Generex Biotechnology Corporation and the purchaser(s) listed on the signature pages thereto
99.1
Press Release dated January 31, 2012